Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy

AIM: Pancreatic ductal adenocarcinoma (PDAC) has the lowest survival rate of all major cancers. Chemotherapy is the mainstay systemic therapy for PDAC, and chemoresistance is a major clinical problem leading to therapeutic failure. This study aimed to identify key differences in gene expression prof...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahni, Sumit, Nahm, Christopher, Ahadi, Mahsa S., Sioson, Loretta, Byeon, Sooin, Chou, Angela, Maloney, Sarah, Moon, Elizabeth, Pavlakis, Nick, Gill, Anthony J., Samra, Jaswinder, Mittal, Anubhav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523964/
https://www.ncbi.nlm.nih.gov/pubmed/37533202
http://dx.doi.org/10.1002/cam4.6411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523964/
https://www.ncbi.nlm.nih.gov/pubmed/37533202
http://dx.doi.org/10.1002/cam4.6411

Ejemplares similares